完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Yufeng Jane TSENG | en_US |
dc.contributor.author | Yu-Li LIU | en_US |
dc.contributor.author | Chung-Ming SUN | en_US |
dc.contributor.author | Hai-Gwo HWU | en_US |
dc.contributor.author | Chih-Min LIU | en_US |
dc.contributor.author | Wen-Sung LAI | en_US |
dc.date.accessioned | 2019-04-11T05:42:29Z | - |
dc.date.available | 2019-04-11T05:42:29Z | - |
dc.date.issued | 2017-02-09 | en_US |
dc.identifier.govdoc | C12Q001/26 | en_US |
dc.identifier.govdoc | A61K031/551 | en_US |
dc.identifier.govdoc | A61K031/485 | en_US |
dc.identifier.govdoc | A61K031/341 | en_US |
dc.identifier.govdoc | A61K031/4706 | en_US |
dc.identifier.govdoc | A61K031/4439 | en_US |
dc.identifier.govdoc | A61K031/451 | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/151250 | - |
dc.description.abstract | The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay. | en_US |
dc.language.iso | en_US | en_US |
dc.title | USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS | en_US |
dc.type | Patents | en_US |
dc.citation.patentcountry | USA | en_US |
dc.citation.patentnumber | 20170037448 | en_US |
顯示於類別: | 專利資料 |